Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy

“Approximately 1/3 of the patients with advanced non-small cell lung cancer (NSCLC) will initially respond to platinum-based chemotherapy, but virtually all tumors will progress (acquired resistance). The remainder will progress during initial treatment (primary resistance). In this study, we test whether the treatment can be improved by inhibiting hepatoma-derived growth factor (HDGF).”